Isentress is the first Merck product to go through our new manufacturing commercialization process, and the
results are impressive – especially for patients who needed Isentress as soon as possible.
As part of the new process, Merck was mass producing our new medicine before clinical development was even completed.
More than 18 months before its expected launch, our manufacturing facilities in Ballydine, Ireland, and Elkton, Va.,
were already producing large amounts of Isentress both for clinical trials and for the market after approval, instead
of waiting to move to full-scale production once the product was approved.
As a result, we were able to meet our accelerated development timelines
and had Isentress on pharmacists’ shelves just four business days after FDA approval.
New Treatment/New Hope:
For 20 years, Scott Gilmore’s blood tests have consistently revealed detectable levels of the HIV virus.
Not anymore. Since adding Isentress to his other antiretroviral medicines, his viral load has fallen – for the
first time ever – to undetectable levels. Although not everyone responds so dramatically, Scott’s experience shows
why Isentress is bringing hope to so many patients and their physicians.
Merck.com is best viewed with Adobe Flash.
